Helicobacter pylori urease antibody test positive

Positive detection of helicobacter pylori urease antibody usually indicates current or past Helicobacter pylori infection, and should be judged comprehensively based on clinical symptoms and other test results. Helicobacter pylori infection may cause chronic gastritis, gastric ulcers, duodenal ulcers and other diseases, and in rare cases, it is associated with the occurrence of gastric cancer.

Helicobacter pylori urease antibody detection determines infection status by detecting specific antibodies against the urease of the bacteria in the blood. Positive antibodies may reflect residual antibodies after current or previous infections, and individual test results cannot distinguish between active infections and previous infections. Most infected individuals may experience digestive symptoms such as upper abdominal pain, postprandial fullness, acid reflux, and belching, while some patients may not have significant discomfort. Long term untreated Helicobacter pylori infection may lead to pathological changes such as gastric mucosal atrophy and intestinal metaplasia. In rare cases, false positives may occur in antibody testing, such as recent use of antibiotics, bismuth agents, or proton pump inhibitors, which may affect the accuracy of the test. Patients with weakened immune function may have lower antibody titers. The association between Helicobacter pylori infection and certain extragastric diseases such as iron deficiency anemia and idiopathic thrombocytopenic purpura remains controversial. The infection rate of Helicobacter pylori is higher in patients with gastric mucosa associated lymphoid tissue lymphoma.

It is recommended that individuals who test positive undergo current infection tests such as carbon-13 or carbon-14 urea breath tests and fecal antigen testing. In daily life, pay attention to the serving of individual dishes, avoid sharing tableware, and reduce the intake of spicy and stimulating food. Family members of infected individuals are advised to undergo simultaneous screening. For eradication treatment, it is necessary to strictly follow medical advice and complete the entire medication process to avoid self discontinuation and drug resistance. After 4-8 weeks of treatment, a follow-up examination should be conducted to confirm the eradication effect, and gastroscopy examination can help evaluate the degree of gastric mucosal lesions.